KalVista Pharmaceuticals, Inc. (KALV)
17.00
+0.57
(+3.47%)
USD |
NASDAQ |
Mar 20, 16:00
16.66
-0.34
(-2.00%)
After-Hours: 20:00
KalVista Pharmaceuticals Research and Development Expense (Quarterly) : 11.99M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | 86.27M |
| Recursion Pharmaceuticals, Inc. | 83.34M |
| Tango Therapeutics, Inc. | 31.62M |
| Modular Medical, Inc. | 4.975M |
| Iovance Biotherapeutics, Inc. | 71.20M |